A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

April 9, 2024

Study Completion Date

April 9, 2024

Conditions
Open Angle Glaucoma
Interventions
DRUG

ONL1204 Ophthalmic solution (Dose A)

Liquid formulation administered by intravitreal (IVT) injection

DRUG

ONL1204 Ophthalmic solution (Dose B)

Liquid formulation administered by intravitreal (IVT) injection

PROCEDURE

Sham procedure

A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.

Trial Locations (11)

1050

Eye Institute Limited, Remuera

2000

Eye Associates, Sydney

2150

PersonalEYES, Parramatta

2220

Sydney Eye Surgeons, Hurstville

2640

Albury Eye Clinic Wodonga, Albury

3002

Centre for Eye Research Australia (CERA), Melbourne

3065

Melbourne Eye Specialists, Fitzroy

3143

Armadale Eye Clinic, Armadale

3150

Waverely Eye Clinic, Waverley

3403

North West Eye Specialists, Gladstone Park

6011

Capital Eye Specialists, Wellington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ONL Therapeutics

INDUSTRY

NCT05160805 - A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma | Biotech Hunter | Biotech Hunter